Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATECNASDAQ:LMATNASDAQ:NVCRNASDAQ:TNDM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATECAlphatec$10.86-0.7%$11.81$4.88▼$13.14$1.60B1.12.06 million shs2.14 million shsLMATLeMaitre Vascular$83.38+2.0%$83.82$71.42▼$109.58$1.85B0.83169,875 shs120,454 shsNVCRNovoCure$16.61-0.5%$17.54$14.17▼$34.13$1.86B0.741.18 million shs767,961 shsTNDMTandem Diabetes Care$20.22$20.31$15.75▼$48.24$1.35B1.521.50 million shs1.33 million shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATECAlphatec-0.73%-1.45%-12.77%+5.23%+7.63%LMATLeMaitre Vascular+1.96%+1.56%+2.43%-2.00%+2.31%NVCRNovoCure-0.48%-7.26%-10.41%-11.51%-12.90%TNDMTandem Diabetes Care0.00%+0.90%-2.41%0.00%-52.80%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATECAlphatec4.4771 of 5 stars3.43.00.03.33.04.20.6LMATLeMaitre Vascular2.8179 of 5 stars2.22.03.30.02.42.51.3NVCRNovoCure4.2732 of 5 stars3.34.00.04.53.51.70.0TNDMTandem Diabetes Care4.1198 of 5 stars4.21.00.04.92.90.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATECAlphatec 2.89Moderate Buy$17.8964.72% UpsideLMATLeMaitre Vascular 2.33Hold$97.8317.33% UpsideNVCRNovoCure 2.67Moderate Buy$32.8397.67% UpsideTNDMTandem Diabetes Care 2.40Hold$33.4365.32% UpsideCurrent Analyst Ratings BreakdownLatest NVCR, TNDM, LMAT, and ATEC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025ATECAlphatecLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$18.006/16/2025TNDMTandem Diabetes CareTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold$24.005/22/2025TNDMTandem Diabetes CareCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$20.00 ➝ $24.005/2/2025ATECAlphatecPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$13.00 ➝ $15.005/2/2025ATECAlphatecNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.005/1/2025TNDMTandem Diabetes CareCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$58.00 ➝ $59.005/1/2025TNDMTandem Diabetes CareStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$60.00 ➝ $31.005/1/2025TNDMTandem Diabetes CareWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$22.00 ➝ $20.005/1/2025TNDMTandem Diabetes CarePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$36.00 ➝ $30.005/1/2025TNDMTandem Diabetes CareRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$33.00 ➝ $24.004/23/2025NVCRNovoCurePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$42.00 ➝ $34.00(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATECAlphatec$611.56M2.60N/AN/A($0.10) per share-108.60LMATLeMaitre Vascular$219.86M8.57$2.44 per share34.24$15.00 per share5.56NVCRNovoCure$605.22M3.06N/AN/A$3.33 per share4.99TNDMTandem Diabetes Care$940.20M1.43N/AN/A$4.01 per share5.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATECAlphatec-$162.12M-$1.15N/AN/AN/A-25.77%-1,657.19%-21.53%7/30/2025 (Estimated)LMATLeMaitre Vascular$44.04M$1.9842.1138.422.1619.96%13.53%9.78%7/30/2025 (Estimated)NVCRNovoCure-$168.63M-$1.51N/AN/AN/A-26.41%-45.46%-13.34%7/24/2025 (Estimated)TNDMTandem Diabetes Care-$96.03M-$2.78N/AN/AN/A-18.71%-57.33%-13.48%7/30/2025 (Estimated)Latest NVCR, TNDM, LMAT, and ATEC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025Q1 2025ATECAlphatec-$0.12-$0.35-$0.23-$0.35$167.57 million$169.18 million5/1/2025Q1 2025LMATLeMaitre Vascular$0.50$0.48-$0.02$0.48$57.61 million$59.87 million4/30/2025Q1 2025TNDMTandem Diabetes Care-$0.60-$0.67-$0.07-$1.97$220.19 million$234.42 million4/24/2025Q1 2025NVCRNovoCure-$0.47-$0.31+$0.16-$0.31$147.57 million$154.99 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATECAlphatecN/AN/AN/AN/AN/ALMATLeMaitre Vascular$0.800.96%N/A40.40%14 YearsNVCRNovoCureN/AN/AN/AN/AN/ATNDMTandem Diabetes CareN/AN/AN/AN/AN/ALatest NVCR, TNDM, LMAT, and ATEC DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/29/2025LMATLeMaitre Vascularquarterly$0.201%5/15/20255/15/20255/29/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATECAlphatecN/A2.751.67LMATLeMaitre Vascular0.4816.4913.83NVCRNovoCure0.271.471.41TNDMTandem Diabetes Care1.992.301.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATECAlphatec66.35%LMATLeMaitre Vascular84.64%NVCRNovoCure84.61%TNDMTandem Diabetes CareN/AInsider OwnershipCompanyInsider OwnershipATECAlphatec22.80%LMATLeMaitre Vascular9.50%NVCRNovoCure5.52%TNDMTandem Diabetes Care1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATECAlphatec700146.17 million112.85 millionOptionableLMATLeMaitre Vascular49022.59 million20.45 millionOptionableNVCRNovoCure1,488111.49 million105.33 millionOptionableTNDMTandem Diabetes Care2,65066.61 million65.34 millionOptionableNVCR, TNDM, LMAT, and ATEC HeadlinesRecent News About These CompaniesTNDM Stock Gains on t:slim X2's Compatibility With FreeStyle Libre 3 +June 23 at 10:51 AM | zacks.comTandem continues to deliver more options, benefits for those with diabetesJune 22 at 3:58 PM | massdevice.comTandem Diabetes Care (NASDAQ:TNDM) Stock Rating Lowered by Wall Street ZenJune 21 at 2:54 AM | marketbeat.comStudy backs Tandem automated insulin delivery in pregnant women with type 1 diabetesJune 21 at 12:08 AM | drugdeliverybusiness.comTandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.June 20, 2025 | drugdeliverybusiness.comTandem Diabetes Care Announces t:slim X2™ Insulin Pump Compatibility with Abbott’s FreeStyle Libre® 3 Plus Sensor in the United StatesJune 20, 2025 | uk.finance.yahoo.comTandem Diabetes Care Announces t:slim X2™ Insulin Pump Compatibility with Abbott's FreeStyle Libre® 3 Plus Sensor in the United StatesJune 20, 2025 | businesswire.comChicago Capital LLC Has $397,000 Stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)June 18, 2025 | marketbeat.comGAMMA Investing LLC Increases Stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)June 18, 2025 | marketbeat.comTruist Financial Initiates Coverage on Tandem Diabetes Care (NASDAQ:TNDM)June 18, 2025 | americanbankingnews.comTruist Financial Begins Coverage on Tandem Diabetes Care (NASDAQ:TNDM)June 16, 2025 | marketbeat.comTandem Diabetes Care (NASDAQ:TNDM) Trading Down 4.4% - Here's WhyJune 12, 2025 | marketbeat.comAbbott to pair glucose-ketone sensor with Tandem's insulin pumpsJune 10, 2025 | modernhealthcare.comTandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitorJune 10, 2025 | drugdeliverybusiness.comTandem Diabetes Care (NASDAQ:TNDM) Stock Price Up 7.1% - Should You Buy?June 10, 2025 | marketbeat.comTandem Diabetes Care Announces Agreement with Abbott for Integration of Automated Insulin Delivery Systems with Future Glucose-Ketone SensorJune 10, 2025 | finance.yahoo.comTandem Diabetes Care (NASDAQ:TNDM) Upgraded by Wall Street Zen to Hold RatingJune 7, 2025 | marketbeat.comTandem Diabetes Care: A Barbell Bet On A High-Stakes TurnaroundJune 5, 2025 | seekingalpha.comTandem Diabetes at Jefferies: Expanding Market HorizonsJune 4, 2025 | investing.comDo You Believe in the Long-Term Growth Potential of Tandem Diabetes Care (TNDM)?June 4, 2025 | insidermonkey.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stock Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)June 3, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNVCR, TNDM, LMAT, and ATEC Company DescriptionsAlphatec NASDAQ:ATEC$10.86 -0.08 (-0.73%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$11.08 +0.23 (+2.07%) As of 06/23/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec surface modifications, Calibrate PSX, and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissues; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.LeMaitre Vascular NASDAQ:LMAT$83.38 +1.60 (+1.96%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$83.38 0.00 (-0.01%) As of 06/23/2025 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.NovoCure NASDAQ:NVCR$16.61 -0.08 (-0.48%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$16.64 +0.03 (+0.18%) As of 06/23/2025 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.Tandem Diabetes Care NASDAQ:TNDM$20.22 0.00 (0.00%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$20.39 +0.17 (+0.82%) As of 06/23/2025 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
